Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2002

View Archived Issues

diaDexus and Emory University form cancer collaboration to target Nox-1 enzyme

Enact reports titanium-based organometallic compounds as anticancer agents

Epothilones: multimedia presentation of mechanisms of action in Part II of an Integrity Case Study

Phase III trial of tecadenoson in PSVT meets primary endpoint

La Jolla set to complete LJP-394 phase III enrollment

Improved quality of life reported for long-acting risperidone in schizophrenia

License agreement for Collagenex's IMPACS compounds for aortic aneurysms

Potential use of a new conjugated estrogen tablet for postmenopausal hot flushes

Genaera provides Lomucin update in cystic fibrosis and asthma

Novel macrolide antibiotics covered by Enanta patent

AstraZeneca presents novel GnRH antagonists for cancer, BPH and uterine myoma

GlaxoSmithKline licenses Kissei's selective inhibitors of renal glucose transport for diabetes

CYP1B1-activated prodrugs of antitumor compound identified by U. of London researchers

Clofarabine enters phase I/II trial in combination with ara-C

French researchers describe 5-HT4 ligands with potential in GI and other disorders

Novel antiproliferative agents prepared at Temple University

New DHFR inhibitors in early development at Melacure

NCX-4016 IND cleared for phase II

Rega Institute claims novel antiviral compounds

GSK and Biovitrum collaborate on 5-HT2C receptor agonists for obesity and other disorders

Inhibitor of p56lck tyrosine kinase and its use in rheumatoid arthritis

Interim results from phase II gastric cancer trial of pemtumomab presented

First potent inhibitors of glutamate racemase with antipneumococcal activity

Anti-fstZ PNA molecule with activity against Gram-negative bacteria

Antidiabetic, hypolipidemic and insulin-sensitizing properties described for novel thiazolidinedione

Baxter submits MAA in E.U. for rAHF-PFM

Prandin approved as combination therapy with rosiglitazone or pioglitazone for type 2 diabetes

Amylin withdraws Symlin MAA in E.U. with plans to resubmit

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...